Fagron North America: Making Fagron Great !
Today, we briefly discuss Fagron's half year results. As indicated before, in previous notes and our company note, the key 2 regions for Fagron's future are EMEA and North America. The latter will almost surely overtake Europe in terms of revenue, however, EMEA is still the cash engine for the company. LATAM remains a question mark for now, as it is unclear how Fagron will alleviate Brazil's competitive pressure. That stated, it is clear that Fagron is poised for long term growth, thus we firmly re-iterate our Buy rating and € 20 PT.Fagron supplies products, services to professionals and institutions in the healthcare sector in Europe, the U.S.A. and Brazil. Co.'s activities are subdivided into four divisions. Through Fagron, Co. offers products and concepts for pharmaceutical compounding. Through Arseus Dental, Co. supplies dental products and concepts to dentists and dental laboratories in Belgium, the Netherlands, France, Germany and Switzerland. Through Arseus Medical, Co. supplies medical and surgical products to specialists, elderly homes, homecare nurses and hospitals in Belgium and the Netherlands. Through Corilus, Co. supplies ICT total solutions for medical specialists in Belgium, the Netherlands and France.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.